Pregabalin | CAS#148553-50-8

MedKoo Cat#: 326760 | Name: Pregabalin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pregabalin is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its use for epilepsy is as an add-on therapy for partial seizures with or without secondary generalization in adults. Some off-label uses of pregabalin include, restless leg syndrome, migraine, social phobia, panic disorder, mania, bipolar disorder, and alcohol withdrawal. Pregabalin is discontinued.

Chemical Structure

Pregabalin

CAS#148553-50-8

Theoretical Analysis

MedKoo Cat#: 326760

Name: Pregabalin

CAS#: 148553-50-8

Chemical Formula: C8H17NO2

Exact Mass: 159.1259

Molecular Weight: 159.23

Elemental Analysis: C, 60.35; H, 10.76; N, 8.80; O, 20.10

Price and Availability

This product was removed for the commercial reasons.

Related CAS #

No Data

Synonym

(R-)-3-Isobutyl GABA; PD 144723; PD-144723; PD144723; CI 1008; CI-1008; HSDB 7530; Lyrica; Pregabalin

IUPAC/Chemical Name

(S)-3-(Aminomethyl)-5-methylhexanoic acid

InChi Key

AYXYPKUFHZROOJ-ZETCQYMHSA-N

InChi Code

InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1

SMILES Code

CC(C)C[C@H](CN)CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 159.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol. 2016 May 17. pii: S0190-9622(16)01507-3. doi: 10.1016/j.jaad.2016.02.1237. [Epub ahead of print] Review. PubMed PMID: 27206757. 2: Griffin E, Brown JN. Pregabalin for the Treatment of Restless Legs Syndrome. Ann Pharmacother. 2016 Jul;50(7):586-91. doi: 10.1177/1060028016643097. Epub 2016 Apr 18. Review. PubMed PMID: 27091870. 3: Bhusal S, Diomampo S, Magrey MN. Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug Healthc Patient Saf. 2016 Feb 17;8:13-23. doi: 10.2147/DHPS.S95535. eCollection 2016. Review. PubMed PMID: 26937205; PubMed Central PMCID: PMC4762578. 4: Gurusamy KS, Lusuku C, Davidson BR. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Cochrane Database Syst Rev. 2016 Feb 2;2:CD011522. doi: 10.1002/14651858.CD011522.pub2. Review. PubMed PMID: 26836292. 5: Robertson K, Marshman LA, Plummer D. Pregabalin and gabapentin for the treatment of sciatica. J Clin Neurosci. 2016 Apr;26:1-7. doi: 10.1016/j.jocn.2015.05.061. Epub 2015 Nov 26. Review. PubMed PMID: 26633090. 6: Lam DM, Choi SW, Wong SS, Irwin MG, Cheung CW. Efficacy of Pregabalin in Acute Postoperative Pain Under Different Surgical Categories: A Meta-Analysis. Medicine (Baltimore). 2015 Nov;94(46):e1944. doi: 10.1097/MD.0000000000001944. Review. PubMed PMID: 26579802; PubMed Central PMCID: PMC4652811. 7: Hwang SH, Park IJ, Cho YJ, Jeong YM, Kang JM. The efficacy of gabapentin/pregabalin in improving pain after tonsillectomy: A meta-analysis. Laryngoscope. 2016 Feb;126(2):357-66. doi: 10.1002/lary.25636. Epub 2015 Sep 25. Review. PubMed PMID: 26404562. 8: Baldwin DS, den Boer JA, Lyndon G, Emir B, Schweizer E, Haswell H. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol. 2015 Oct;29(10):1047-60. doi: 10.1177/0269881115598411. Epub 2015 Aug 10. Review. PubMed PMID: 26259772. 9: Eipe N, Penning J, Yazdi F, Mallick R, Turner L, Ahmadzai N, Ansari MT. Perioperative use of pregabalin for acute pain-a systematic review and meta-analysis. Pain. 2015 Jul;156(7):1284-300. doi: 10.1097/j.pain.0000000000000173. Review. PubMed PMID: 25830925. 10: Juhn MS, Parsons B, Varvara R, Sadosky A. Pregabalin for painful diabetic peripheral neuropathy: strategies for dosing, monotherapy vs. combination therapy, treatment-refractory patients, and adverse events. Curr Med Res Opin. 2015 May;31(5):1017-26. doi: 10.1185/03007995.2015.1030375. Epub 2015 Apr 1. Review. PubMed PMID: 25772233. 11: Kawalec P, Cierniak A, Pilc A, Nowak G. Pregabalin for the treatment of social anxiety disorder. Expert Opin Investig Drugs. 2015 Apr;24(4):585-94. doi: 10.1517/13543784.2014.979283. Epub 2014 Oct 31. Review. PubMed PMID: 25361817. 12: Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015 Jan;114(1):10-31. doi: 10.1093/bja/aeu293. Epub 2014 Sep 10. Review. PubMed PMID: 25209095. 13: Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014 Sep;28(9):835-54. doi: 10.1007/s40263-014-0192-0. Review. PubMed PMID: 25149863. 14: Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014 Feb;5(1):38-56. doi: 10.1177/2042098613505614. Review. PubMed PMID: 25083261; PubMed Central PMCID: PMC4110876. 15: Parker L, Huelin R, Khankhel Z, Wasiak R, Mould J. A systematic review of pharmacoeconomic studies for pregabalin. Pain Pract. 2015 Jan;15(1):82-94. doi: 10.1111/papr.12193. Epub 2014 May 10. Review. PubMed PMID: 24815038. 16: Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014 Jun;28(6):491-6. doi: 10.1007/s40263-014-0164-4. Review. PubMed PMID: 24760436. 17: Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Mar 12;(3):CD005612. doi: 10.1002/14651858.CD005612.pub3. Review. PubMed PMID: 24623260. 18: Reyes-Molón L, Gallego-Deike L. [Pregabalin as a probable cause of thrombocytopenia: presentation of two clinical cases and review of literature]. Actas Esp Psiquiatr. 2014 Jan-Feb;42(1):39-40. Epub 2014 Jan 1. Review. Spanish. PubMed PMID: 24504992. 19: Keshavarz K, Hashemi-Meshkini A, Gharibnaseri Z, Nikfar S, Kebriaeezadeh A, Abdollahi M. A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience. Arch Med Sci. 2013 Dec 30;9(6):961-7. doi: 10.5114/aoms.2013.39617. Epub 2013 Dec 26. Review. PubMed PMID: 24482637; PubMed Central PMCID: PMC3902716. 20: Darbà J, Kaskens L, Pérez C, Álvarez E, Navarro-Artieda R, Sicras-Mainar A. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. Adv Ther. 2014 Jan;31(1):1-29. doi: 10.1007/s12325-013-0088-2. Epub 2014 Jan 4. Review. PubMed PMID: 24390901.